These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
253 related items for PubMed ID: 9268186
1. Effect of depolymerized holothurian glycosaminoglycan (DHG) on tissue factor pathway inhibitor: in vitro and in vivo studies. Nagase H, Enjyoji K, Kamikubo Y, Kitazato KT, Kitazato K, Saito H, Kato H. Thromb Haemost; 1997 Aug; 78(2):864-70. PubMed ID: 9268186 [Abstract] [Full Text] [Related]
2. Antithrombin III-independent effect of depolymerized holothurian glycosaminoglycan (DHG) on acute thromboembolism in mice. Nagase H, Kitazato KT, Sasaki E, Hattori M, Kitazato K, Saito H. Thromb Haemost; 1997 Feb; 77(2):399-402. PubMed ID: 9157603 [Abstract] [Full Text] [Related]
3. Antithrombotic and anticoagulant activity of depolymerized fragment of the glycosaminoglycan extracted from Stichopus japonicus Selenka. Suzuki N, Kitazato K, Takamatsu J, Saito H. Thromb Haemost; 1991 Apr 08; 65(4):369-73. PubMed ID: 1647552 [Abstract] [Full Text] [Related]
4. Tissue factor pathway inhibitor; its structure, function and clinical significance. Kato H. Pol J Pharmacol; 1996 Apr 08; 48(1):67-72. PubMed ID: 9112630 [Abstract] [Full Text] [Related]
5. The role of catalytic cleft and exosite residues of factor VIIa for complex formation with tissue factor pathway inhibitor. Iakhiaev A, Ruf W, Rao LV. Thromb Haemost; 2001 Mar 08; 85(3):458-63. PubMed ID: 11307815 [Abstract] [Full Text] [Related]
6. Prolonged bleeding time induced by anticoagulant glycosaminoglycans in dogs is associated with the inhibition of thrombin-induced platelet aggregation. Kitazato K, Kitazato KT, Sasaki E, Minamiguchi K, Nagase H. Thromb Res; 2003 Mar 08; 112(1-2):83-91. PubMed ID: 15013278 [Abstract] [Full Text] [Related]
7. Kinetics of the inhibition of tissue factor-factor VIIa by tissue factor pathway inhibitor. Lindhout T, Franssen J, Willems G. Thromb Haemost; 1995 Sep 08; 74(3):910-5. PubMed ID: 8571320 [Abstract] [Full Text] [Related]
8. Monoclonal antibody specific for tissue factor pathway inhibitor-factor Xa complex: its characterization and application to plasmas from patients with disseminated intravascular coagulation and pre-disseminated intravascular coagulation. Ohkura N, Soe G, Kohno I, Kumeda K, Wada H, Kamikubo Y, Shiku H, Kato H. Blood Coagul Fibrinolysis; 1999 Sep 08; 10(6):309-19. PubMed ID: 10493212 [Abstract] [Full Text] [Related]
9. Activity of secreted Kunitz domain 1 variants of tissue factor pathway inhibitor. Johnson K, Zaror I, Bauer D, Choi Y, Creasey A, Innis M. Thromb Haemost; 1998 Oct 08; 80(4):585-7. PubMed ID: 9798974 [Abstract] [Full Text] [Related]
10. Inhibition of factor X activation at extracellular matrix of fibroblasts during flow conditions: a comparison between tissue factor pathway inhibitor and inactive factor VIIa. Valentin S, Reutlingsperger CP, Nordfang O, Lindhout T. Thromb Haemost; 1995 Dec 08; 74(6):1478-85. PubMed ID: 8772224 [Abstract] [Full Text] [Related]
11. Protein S stimulates inhibition of the tissue factor pathway by tissue factor pathway inhibitor. Hackeng TM, Seré KM, Tans G, Rosing J. Proc Natl Acad Sci U S A; 2006 Feb 28; 103(9):3106-11. PubMed ID: 16488980 [Abstract] [Full Text] [Related]
12. Anticoagulant actions of tissue factor pathway inhibitor on tissue-factor-dependent plasma coagulation. Ofosu FA. Semin Thromb Hemost; 1995 Feb 28; 21(2):240-4. PubMed ID: 7660146 [Abstract] [Full Text] [Related]
13. Depolymerized holothurian glycosaminoglycan with novel anticoagulant actions: antithrombin III- and heparin cofactor II-independent inhibition of factor X activation by factor IXa-factor VIIIa complex and heparin cofactor II-dependent inhibition of thrombin. Nagase H, Enjyoji K, Minamiguchi K, Kitazato KT, Kitazato K, Saito H, Kato H. Blood; 1995 Mar 15; 85(6):1527-34. PubMed ID: 7888673 [Abstract] [Full Text] [Related]
14. Enhancement of lipoprotein lipase activity by tissue factor pathway inhibitor. Mukherjee M, Kakkar VV. Thromb Haemost; 1999 Dec 15; 82(6):1648-51. PubMed ID: 10613650 [Abstract] [Full Text] [Related]
15. Factor Xa cleavage of tissue factor pathway inhibitor is associated with loss of anticoagulant activity. Salemink I, Franssen J, Willems GM, Hemker HC, Li A, Wun TC, Lindhout T. Thromb Haemost; 1998 Aug 15; 80(2):273-80. PubMed ID: 9716152 [Abstract] [Full Text] [Related]
16. The importance of the binding of factor Xa to phospholipids in the inhibitory mechanism of tissue factor pathway inhibitor: the transmembrane and cytoplasmic domains of tissue factor are not essential for the inhibitory action of tissue factor pathway inhibitor. Kazama Y. Thromb Haemost; 1997 Mar 15; 77(3):492-7. PubMed ID: 9066000 [Abstract] [Full Text] [Related]
17. Anticoagulant versus amidolytic activity of tissue factor pathway inhibitor in coronary artery disease. Mukherjee M, Ranlall N, Patel G, Rutlin A, Jehanli A, Kakkar VV. Blood Coagul Fibrinolysis; 2000 Apr 15; 11(3):285-91. PubMed ID: 10870809 [Abstract] [Full Text] [Related]
18. Structural and functional characterization of tissue factor pathway inhibitor following degradation by matrix metalloproteinase-8. Cunningham AC, Hasty KA, Enghild JJ, Mast AE. Biochem J; 2002 Oct 15; 367(Pt 2):451-8. PubMed ID: 12117418 [Abstract] [Full Text] [Related]
19. Tissue factor pathway inhibitor (TFPI). Rucińska M, Gacko M, Skrzydlewski Z. Rocz Akad Med Bialymst; 1997 Oct 15; 42 Suppl 1():118-22. PubMed ID: 9337530 [Abstract] [Full Text] [Related]
20. The significance of TFPI in clotting assays--comparison and combination with other anticoagulants. Nordfang O, Kristensen HI, Valentin S, Ostergaard P, Wadt J. Thromb Haemost; 1993 Sep 01; 70(3):448-53. PubMed ID: 8259547 [Abstract] [Full Text] [Related] Page: [Next] [New Search]